| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Failure, Acute | 9 | 2024 | 88 | 2.020 |
Why?
|
| Liver Transplantation | 20 | 2025 | 1033 | 2.020 |
Why?
|
| Hypertension, Portal | 5 | 2017 | 80 | 1.560 |
Why?
|
| Chemical and Drug Induced Liver Injury | 5 | 2024 | 106 | 1.450 |
Why?
|
| Hepatic Encephalopathy | 14 | 2015 | 75 | 1.390 |
Why?
|
| Acetaminophen | 6 | 2024 | 92 | 1.340 |
Why?
|
| Extracorporeal Circulation | 9 | 2019 | 54 | 1.190 |
Why?
|
| Hypertension, Pulmonary | 5 | 2017 | 428 | 1.180 |
Why?
|
| Liver Failure | 6 | 2017 | 93 | 1.060 |
Why?
|
| Liver, Artificial | 4 | 2014 | 9 | 1.050 |
Why?
|
| Artificial Organs | 9 | 1996 | 14 | 1.040 |
Why?
|
| Drug Overdose | 5 | 2024 | 65 | 1.020 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2025 | 23 | 0.990 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2024 | 57 | 0.830 |
Why?
|
| Liver | 16 | 2024 | 1858 | 0.790 |
Why?
|
| Hepacivirus | 3 | 2018 | 242 | 0.790 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2019 | 2 | 0.650 |
Why?
|
| Hepatocytes | 4 | 2012 | 256 | 0.650 |
Why?
|
| Hepatitis C | 3 | 2018 | 368 | 0.630 |
Why?
|
| Analgesics | 1 | 2019 | 129 | 0.630 |
Why?
|
| Alcoholism | 2 | 2024 | 229 | 0.590 |
Why?
|
| Ammonia | 2 | 2015 | 68 | 0.510 |
Why?
|
| Rifamycins | 1 | 2015 | 21 | 0.500 |
Why?
|
| Lactulose | 1 | 2015 | 39 | 0.500 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 14 | 0.490 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 61 | 0.480 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 54 | 0.470 |
Why?
|
| Models, Statistical | 2 | 2017 | 447 | 0.460 |
Why?
|
| Hepatitis C, Chronic | 3 | 2016 | 319 | 0.450 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 178 | 0.440 |
Why?
|
| Disease Eradication | 1 | 2014 | 34 | 0.440 |
Why?
|
| Antiviral Agents | 3 | 2016 | 736 | 0.420 |
Why?
|
| Humans | 58 | 2025 | 122410 | 0.400 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 337 | 0.390 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2011 | 8 | 0.380 |
Why?
|
| Citrullinemia | 1 | 2010 | 15 | 0.360 |
Why?
|
| Models, Biological | 2 | 2013 | 1439 | 0.360 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2023 | 47 | 0.350 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2008 | 2 | 0.320 |
Why?
|
| Iron Overload | 1 | 2008 | 14 | 0.320 |
Why?
|
| Anemia, Sideroblastic | 1 | 2008 | 17 | 0.320 |
Why?
|
| Biomedical Research | 1 | 2014 | 510 | 0.310 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2008 | 65 | 0.310 |
Why?
|
| Cation Transport Proteins | 1 | 2008 | 99 | 0.300 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 391 | 0.290 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2007 | 7 | 0.290 |
Why?
|
| Liver Cirrhosis | 2 | 2011 | 824 | 0.280 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 203 | 0.280 |
Why?
|
| Ascites | 1 | 2007 | 88 | 0.270 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2004 | 151 | 0.270 |
Why?
|
| Hepatitis E | 1 | 2006 | 5 | 0.270 |
Why?
|
| Tissue Donors | 3 | 2018 | 498 | 0.260 |
Why?
|
| Epoprostenol | 1 | 2006 | 67 | 0.260 |
Why?
|
| Liver Diseases | 3 | 2018 | 384 | 0.240 |
Why?
|
| Travel | 1 | 2006 | 117 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 278 | 0.240 |
Why?
|
| Abdominal Pain | 1 | 2007 | 308 | 0.240 |
Why?
|
| Mutation, Missense | 1 | 2008 | 844 | 0.230 |
Why?
|
| Drug Design | 1 | 2004 | 147 | 0.220 |
Why?
|
| Adult | 17 | 2025 | 28746 | 0.200 |
Why?
|
| Treatment Outcome | 8 | 2019 | 12036 | 0.200 |
Why?
|
| Pulmonary Artery | 3 | 2017 | 441 | 0.200 |
Why?
|
| Administration, Oral | 2 | 2014 | 668 | 0.200 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 331 | 0.190 |
Why?
|
| Middle Aged | 16 | 2025 | 25591 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1082 | 0.190 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2000 | 48 | 0.170 |
Why?
|
| Male | 24 | 2025 | 59592 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2023 | 296 | 0.170 |
Why?
|
| Professional Practice Location | 1 | 2019 | 7 | 0.160 |
Why?
|
| Gastroenterologists | 1 | 2019 | 11 | 0.160 |
Why?
|
| Alkaline Phosphatase | 3 | 1989 | 96 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 35 | 0.160 |
Why?
|
| Renal Dialysis | 3 | 1996 | 842 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 172 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2024 | 68 | 0.150 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2018 | 45 | 0.150 |
Why?
|
| Donor Selection | 1 | 2018 | 52 | 0.150 |
Why?
|
| Alanine Transaminase | 3 | 2013 | 155 | 0.150 |
Why?
|
| Hemodynamics | 2 | 2012 | 839 | 0.150 |
Why?
|
| Arterial Pressure | 2 | 2017 | 104 | 0.140 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 218 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 2078 | 0.140 |
Why?
|
| Narcotics | 1 | 2017 | 62 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2019 | 210 | 0.140 |
Why?
|
| Female | 20 | 2025 | 64958 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2016 | 13 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 127 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 490 | 0.130 |
Why?
|
| Graft Survival | 2 | 2019 | 522 | 0.130 |
Why?
|
| Headache | 1 | 2016 | 107 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 76 | 0.130 |
Why?
|
| Time Factors | 4 | 2019 | 6176 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2017 | 220 | 0.130 |
Why?
|
| Ornithine | 1 | 2015 | 25 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2019 | 580 | 0.120 |
Why?
|
| Liver Regeneration | 4 | 1996 | 52 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 13 | 0.120 |
Why?
|
| Glycerol | 1 | 2015 | 91 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 56 | 0.120 |
Why?
|
| Dogs | 5 | 1994 | 774 | 0.120 |
Why?
|
| United States | 7 | 2023 | 10478 | 0.120 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2015 | 75 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2012 | 1300 | 0.120 |
Why?
|
| Phenylbutyrates | 1 | 2015 | 54 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 2814 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2015 | 56 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2024 | 15879 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 99 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2010 | 103 | 0.110 |
Why?
|
| Hepatitis | 1 | 1994 | 65 | 0.110 |
Why?
|
| Prognosis | 5 | 2023 | 4492 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 112 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 110 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 142 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 178 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2013 | 3 | 0.110 |
Why?
|
| Assisted Circulation | 1 | 1993 | 34 | 0.110 |
Why?
|
| Animals | 14 | 2019 | 33888 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 710 | 0.110 |
Why?
|
| Mass Screening | 1 | 2018 | 780 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1247 | 0.100 |
Why?
|
| Schistosomiasis mansoni | 1 | 2012 | 24 | 0.100 |
Why?
|
| Malnutrition | 1 | 2015 | 196 | 0.100 |
Why?
|
| Probiotics | 1 | 2015 | 209 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 42 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1272 | 0.100 |
Why?
|
| Blood Proteins | 1 | 1992 | 116 | 0.100 |
Why?
|
| Hepatectomy | 1 | 1992 | 122 | 0.100 |
Why?
|
| Risk Factors | 5 | 2019 | 9871 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 302 | 0.090 |
Why?
|
| Argininosuccinate Synthase | 1 | 2010 | 20 | 0.090 |
Why?
|
| Aged | 9 | 2025 | 18781 | 0.090 |
Why?
|
| Creatinine | 1 | 2012 | 379 | 0.090 |
Why?
|
| Fibrosis | 1 | 2012 | 429 | 0.090 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2010 | 36 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1146 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1874 | 0.090 |
Why?
|
| Citrulline | 1 | 2010 | 84 | 0.080 |
Why?
|
| Gastroenterology | 1 | 2012 | 190 | 0.080 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 82 | 0.080 |
Why?
|
| Cell Line | 4 | 2000 | 2785 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1727 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 561 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3613 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 124 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 793 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2010 | 872 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 390 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2018 | 5974 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2012 | 0.070 |
Why?
|
| Veterans | 1 | 2018 | 1712 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2013 | 609 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 318 | 0.070 |
Why?
|
| Recurrence | 1 | 2010 | 1412 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 957 | 0.070 |
Why?
|
| Jaundice | 1 | 2006 | 28 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 454 | 0.060 |
Why?
|
| India | 1 | 2006 | 218 | 0.060 |
Why?
|
| Isoenzymes | 1 | 1986 | 223 | 0.060 |
Why?
|
| Lanosterol | 1 | 2025 | 2 | 0.060 |
Why?
|
| Sitosterols | 1 | 2025 | 9 | 0.060 |
Why?
|
| Registries | 2 | 2024 | 1378 | 0.060 |
Why?
|
| Intestines | 1 | 1989 | 580 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 539 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2018 | 540 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2019 | 3306 | 0.060 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2004 | 15 | 0.060 |
Why?
|
| Toxicology | 1 | 2004 | 9 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 1387 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 8805 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2004 | 62 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 481 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 350 | 0.060 |
Why?
|
| Cysteine | 1 | 2024 | 134 | 0.060 |
Why?
|
| Biological Assay | 1 | 2004 | 101 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 618 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2004 | 284 | 0.060 |
Why?
|
| Caspases | 1 | 2004 | 160 | 0.060 |
Why?
|
| Intestine, Small | 1 | 1986 | 313 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2006 | 747 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 288 | 0.050 |
Why?
|
| alpha-Fetoproteins | 2 | 1994 | 136 | 0.050 |
Why?
|
| North America | 1 | 2023 | 234 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2018 | 1161 | 0.050 |
Why?
|
| Serum Albumin | 2 | 1994 | 107 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3076 | 0.050 |
Why?
|
| Coma | 1 | 2023 | 54 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 1986 | 668 | 0.050 |
Why?
|
| RNA | 1 | 1986 | 577 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2025 | 1561 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 126 | 0.050 |
Why?
|
| Equipment Design | 2 | 1994 | 598 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2002 | 36 | 0.050 |
Why?
|
| Ischemia | 1 | 2024 | 342 | 0.050 |
Why?
|
| Biomarkers | 1 | 2010 | 2942 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 607 | 0.050 |
Why?
|
| Triazoles | 1 | 2002 | 137 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 Inhibitors | 1 | 2000 | 3 | 0.050 |
Why?
|
| Theophylline | 1 | 2000 | 29 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 643 | 0.050 |
Why?
|
| Methylcholanthrene | 1 | 2000 | 19 | 0.040 |
Why?
|
| Oxazines | 1 | 2000 | 25 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2000 | 105 | 0.040 |
Why?
|
| Fluorescence | 1 | 2000 | 93 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1994 | 1076 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 2017 | 189 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 27 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 4987 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 191 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 450 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 186 | 0.040 |
Why?
|
| Pregnancy | 1 | 2010 | 7102 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 581 | 0.040 |
Why?
|
| Metagenomics | 1 | 2018 | 109 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2004 | 2315 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 18984 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 492 | 0.030 |
Why?
|
| Mutation | 1 | 2010 | 5786 | 0.030 |
Why?
|
| Jejunum | 2 | 1988 | 128 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 2017 | 121 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 1996 | 68 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 1996 | 304 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 41 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 2782 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 581 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1236 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 524 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 1996 | 140 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 644 | 0.030 |
Why?
|
| Sorption Detoxification | 1 | 1994 | 2 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1005 | 0.030 |
Why?
|
| Giant Cells | 1 | 1994 | 35 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1994 | 91 | 0.030 |
Why?
|
| Survival Rate | 2 | 1996 | 2001 | 0.030 |
Why?
|
| Galactose | 1 | 1994 | 55 | 0.030 |
Why?
|
| Rats | 4 | 1989 | 3660 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 384 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 475 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1293 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1403 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1996 | 1364 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1994 | 147 | 0.030 |
Why?
|
| Life Support Systems | 1 | 1993 | 6 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 864 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1993 | 401 | 0.030 |
Why?
|
| Transferrin | 1 | 1992 | 51 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1988 | 227 | 0.030 |
Why?
|
| Methionine Sulfoximine | 1 | 1992 | 1 | 0.030 |
Why?
|
| Methemoglobinemia | 1 | 1992 | 8 | 0.030 |
Why?
|
| Vacuoles | 1 | 1992 | 24 | 0.030 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1992 | 97 | 0.020 |
Why?
|
| Buthionine Sulfoximine | 1 | 1992 | 28 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 1992 | 51 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2794 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 1577 | 0.020 |
Why?
|
| Carbolines | 1 | 1991 | 6 | 0.020 |
Why?
|
| Critical Care | 1 | 1996 | 647 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3306 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 1991 | 72 | 0.020 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1989 | 1 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 1989 | 24 | 0.020 |
Why?
|
| Phospholipase D | 1 | 1989 | 7 | 0.020 |
Why?
|
| Monensin | 1 | 1989 | 10 | 0.020 |
Why?
|
| Butyric Acid | 1 | 1989 | 7 | 0.020 |
Why?
|
| Microvilli | 1 | 1989 | 73 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1989 | 63 | 0.020 |
Why?
|
| Butyrates | 1 | 1989 | 35 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 1992 | 665 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1989 | 97 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 314 | 0.020 |
Why?
|
| Ileum | 1 | 1989 | 134 | 0.020 |
Why?
|
| Duodenum | 1 | 1989 | 100 | 0.020 |
Why?
|
| Apoproteins | 1 | 1988 | 20 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 1988 | 41 | 0.020 |
Why?
|
| Biopsy | 1 | 1992 | 1252 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1992 | 1090 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6303 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 254 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1988 | 273 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 1986 | 16 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1986 | 16 | 0.020 |
Why?
|
| Contraindications | 1 | 2006 | 77 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1986 | 106 | 0.020 |
Why?
|
| Microsomes | 1 | 1986 | 56 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1986 | 64 | 0.020 |
Why?
|
| Ribavirin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 217 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 1991 | 675 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2006 | 221 | 0.010 |
Why?
|
| Child | 2 | 1994 | 24118 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1402 | 0.010 |
Why?
|
| Peptides | 1 | 1986 | 801 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1989 | 1009 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1936 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1986 | 2701 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2002 | 40 | 0.010 |
Why?
|
| Piperazines | 1 | 2002 | 227 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 175 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1677 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 934 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 1166 | 0.010 |
Why?
|
| Factor V | 1 | 1996 | 17 | 0.010 |
Why?
|
| Platelet Count | 1 | 1996 | 130 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 875 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 169 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1996 | 152 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 1949 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1988 | 2833 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 1988 | 44 | 0.000 |
Why?
|
| Apolipoprotein A-I | 1 | 1988 | 77 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1988 | 155 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1991 | 804 | 0.000 |
Why?
|
| Apolipoproteins E | 1 | 1988 | 188 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 95 | 0.000 |
Why?
|
| Ligation | 1 | 1986 | 134 | 0.000 |
Why?
|
| Triglycerides | 1 | 1988 | 547 | 0.000 |
Why?
|
| Cholesterol | 1 | 1988 | 507 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1986 | 355 | 0.000 |
Why?
|
| Placenta | 1 | 1986 | 490 | 0.000 |
Why?
|